Hypothesis

Aged B cell repertoires suffer from over‑consolidation driven by persistent IgG‑FcγRIIb signaling that raises activation thresholds and suppresses somatic hypermutation. Transient reduction of circulating IgG combined with low‑dose, intermittent TLR7/8 agonist exposure will lower this threshold, reactivate AID activity, and restore clonal diversity without causing autoimmunity.

Mechanistic Basis

Chronic IgG accumulation in senescent tissues engages the inhibitory FcγRIIb receptor on B cells, recruiting SHP‑1 phosphatase and dampening BCR‑mediated signals required for germinal center (GC) entry and AID induction【https://pmc.ncbi.nlm.nih.gov/articles/PMC2853364/】. This creates a self‑reinforcing loop: high IgG → stronger FcγRIIb inhibition → lower AID → reduced SHM → further oligoclonal dominance【https://pmc.ncbi.nlm.nih.gov/articles/PMC2667647/】. TLR7/8 signaling, when delivered in a tonic, sub‑inflammatory manner, can counteract FcγRIIb by activating MyD88‑dependent NF‑κB pathways that up‑regulate AID and promote GC re‑entry【https://pubmed.ncbi.nlm.nih.gov/26614343/】. The combination therefore predicts a synergistic reset: IgG depletion removes the brake, while TLR7/8 stimulation provides the gas.

Predictions

1. In aged mice, a 48‑hour anti‑IgG serum depletion followed by three weekly low‑dose imiquimod (TLR7/8 agonist) injections will increase GC B cell frequency by ≥2‑fold compared with either treatment alone.
2. High‑throughput Ig‑seq will show a significant rise in clonal richness (inverse Simpson index) and a shift toward lower clonal dominance (Gini coefficient ↓30%) after combined therapy.
3. Affinity maturation of a model antigen (e.g., NP‑OVA) will improve, evidenced by higher NP4‑binding/NP1‑binding ratios and increased average mutation load in VH sequences.
4. Autoantibody levels (anti‑dsDNA, RF) will not exceed baseline levels observed in young controls, indicating that plasticity is restored without breaking tolerance.
5. Functional readouts—viral challenge clearance and vaccine titers—will be enhanced relative to untreated aged cohorts.

Experimental Design

• Animals: 20‑month‑old C57BL/6 mice (n=10 per group). Groups: (1) PBS control, (2) anti‑IgG depletion only, (3) TLR7/8 agonist only, (4) combined therapy.
• Depletion: Intraperitoneal injection of 250 µg anti‑mouse IgG (Fc‑specific) 24 h before first agonist dose; repeat after 48 h to maintain low serum IgG for 4 days.
• Agonist: Imiquimod 2 µg in 200 µL saline, topical ear application, three times weekly for 3 weeks.
• Readouts: Flow cytometry for GL7⁺Fas⁺ GC B cells at day 14 and 21; serum IgG ELISA to confirm depletion/re‑pletion; Ig‑seq of sorted GC B cells; autoantibody ELISA; NP‑OVA immunization on day 10 with serum collection day 24 for affinity assessment; lethal influenza challenge at week 4 to assess survival.

Potential Pitfalls & Mitigations

• Excessive B cell activation leading to autoimmunity: Use low‑dose TLR agonist and monitor autoantibodies; if titers rise, reduce frequency or dose.
• Incomplete IgG depletion: Verify serum IgG <10 % of baseline before each agonist cycle; adjust antibody dose accordingly.
• Age‑related stromal changes that may limit GC formation: Include histology of spleens/LNs to assess follicular dendritic cell networks; if impaired, add low‑dose IL‑21 to support Tfh help.

By testing whether removing the inhibitory IgG‑FcγRIIb tone while providing a controlled innate stimulus can reactivate the adaptive diversification machinery, this hypothesis directly challenges the view of immutable B cell decay and offers a concrete, falsifiable route to rejuvenate humoral immunity in aging.